Despite these differences, all trials used independent adjudication committees to enhance outcome validity. These findings are consistent with results seen for dapagliflozin, another SGLT2 inhibitor, which also demonstrated reduced heart failure hospitalizations and cardiovascular benefits in trials like DAPA-HF and DELIVER, supporting a potential class effect [22,23]. The gene discussed is SLC5A2; the disease is heart failure.